Rep. Emily Randall Sells Off Shares of Abbott Laboratories (NYSE:ABT)

Representative Emily Randall (D-Washington) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on February 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on January 6th. The trade occurred in the Representative’s “GARRET D. LEAHEY 2019 IRREVOCABLE F/B/O ALISON LEAHEY” account.

Representative Emily Randall also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 1/7/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Exxon Mobil (NYSE:XOM) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Verizon Communications (NYSE:VZ) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Fortive (NYSE:FTV) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Medtronic (NYSE:MDT) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 1/6/2025.

Abbott Laboratories Stock Performance

Shares of ABT opened at $131.83 on Friday. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $132.50. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The company has a market cap of $228.66 billion, a PE ratio of 17.23, a price-to-earnings-growth ratio of 2.39 and a beta of 0.75. The stock has a 50-day moving average price of $118.34 and a 200-day moving average price of $115.71.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.34. The business had revenue of $10.97 billion during the quarter, compared to analyst estimates of $11.03 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. Abbott Laboratories’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.19 earnings per share. As a group, equities analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be paid a $0.59 dividend. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 dividend on an annualized basis and a yield of 1.79%. The ex-dividend date is Wednesday, January 15th. Abbott Laboratories’s dividend payout ratio is currently 30.85%.

Institutional Investors Weigh In On Abbott Laboratories

Large investors have recently made changes to their positions in the business. Redwood Park Advisors LLC purchased a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Groupama Asset Managment raised its position in shares of Abbott Laboratories by 22.2% in the 3rd quarter. Groupama Asset Managment now owns 228,448 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 41,557 shares during the last quarter. Noble Wealth Management PBC bought a new position in Abbott Laboratories in the 4th quarter worth about $26,000. NewSquare Capital LLC grew its position in Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker’s stock valued at $27,000 after purchasing an additional 105 shares during the last quarter. Finally, WealthTrak Capital Management LLC bought a new stake in Abbott Laboratories during the 4th quarter valued at about $28,000. 75.18% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on ABT. Evercore ISI raised their price target on Abbott Laboratories to $136.00 and gave the company a “buy” rating in a research report on Thursday, January 2nd. Mizuho raised their price objective on Abbott Laboratories from $115.00 to $130.00 and gave the company a “neutral” rating in a report on Thursday, October 17th. Morgan Stanley upped their target price on Abbott Laboratories from $107.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 17th. Piper Sandler lifted their price target on shares of Abbott Laboratories from $131.00 to $133.00 and gave the stock an “overweight” rating in a research note on Thursday, October 17th. Finally, Wells Fargo & Company boosted their price objective on shares of Abbott Laboratories from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $133.06.

Insiders Place Their Bets

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of Abbott Laboratories stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total value of $3,054,573.50. Following the completion of the sale, the executive vice president now owns 125,697 shares of the company’s stock, valued at approximately $16,152,064.50. This trade represents a 15.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.10% of the company’s stock.

About Representative Randall

Emily Randall (Democratic Party) is a member of the U.S. House, representing Washington’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Randall (Democratic Party) is running for re-election to the U.S. House to represent Washington’s 6th Congressional District. She declared candidacy for the 2026 election.

Emily Randall was born in Port Orchard, Washington, and lives in Bremerton, Washington. Randall earned bachelor’s degrees in Spanish and women’s studies from Wellesley College in 2008. Her career experience includes working as a development professional with Wellesley College, the San Francisco AIDS Foundation, Planned Parenthood Federation of America, and Legal Voice.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.